Moatable, Inc.

OTCPK:MTBL.Y Lagerbericht

Marktkapitalisierung: US$820.9k

Moatable Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Die Gewinne von Moatable sind jährlich um durchschnittlich 36.2% gestiegen, während die Gewinne der Branche Software jährlich um gewachsen um 22.4% gestiegen sind. Die Umsätze sind jährlich um gewachsen 27.2% gestiegen.

Wichtige Informationen

36.19%

Wachstumsrate der Gewinne

34.94%

EPS-Wachstumsrate

Software Wachstum der Industrie17.33%
Wachstumsrate der Einnahmen27.20%
Eigenkapitalrendite-6.90%
Netto-Marge-1.77%
Letzte Ertragsaktualisierung30 Sep 2025

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Analyseartikel • Sep 14

We're Keeping An Eye On Moatable's (NYSE:MTBL) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analyseartikel • May 02

Here's Why We're Not Too Worried About Renren's (NYSE:RENN) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Dec 19

Best Idea: Renren And Beyond

Summary Three things I look for when looking at companies. 2022: It was all about Renren. 2023: What ideas are out there? YCharts Best Ideas Each year, I highlight one top position as a best idea for the subsequent year. This year, the idea has been Renren (RENN), one of my top three holdings. How do I pick? I look for three things: Something safe, lucrative, and uncorrelated with the overall markets. Bottoms up! I look for ways to make money in any market – up, down or sideways. Macro prognosticators are far greater in quantity than quality. What I don’t do: Macro I stay out of the whole discussion of which way the stock market will go. I have no idea. I doubt many of the people who make bold macro calls get it right a statistically significant percentage of the time. What I do: Events Instead I focus on discreet corporate events that unlock shareholder value and do detailed firm-level analysis to find and exploit them to make money in any market. What kind of events? Mostly litigation, M&A, and in particular merger securities (which overlaps quite a bit with litigation). What are we really doing here? Counterparty selection. Avoiding being the patsy. Narrowing down who you’re competing against due to narrow mandates and complexity. Renren My best idea for 2022 was Renren. The year is not yet out but with the S&P 500 down 18%, RENN is up over 120% year to date. It started the year under $15. It will end the year with a $31.62 cash distribution. This was the result of a complex litigation that I was intimately involved with for a long time. It was safe, lucrative, and had absolutely nothing whatsoever to do with what the overall stock market did - it just happened to be publicly traded. When first presented, I estimated the probability of its upside scenario at 90%, now that's 100%. Excluding the cash distribution, I estimated that equity stub would be worth at least $1 and maybe as much as $4. Today, it costs under $1. It's exactly what I look for when sizing a top position and picking an annual idea. Spectrum As I approach the decision on what to name my best idea for 2023, I’m looking for another case that will be safe, lucrative, and uncorrelated with the stock market. One candidate is Spectrum Brands (SPB). It finished this past quarter under $40 per share, has recovered a bit but still trades for under $60 and is worth over $80. The kicker, as with Renren, is litigation. The US Department of Justice sued to block a transformative asset sale that would pay SPB in cash more than their entire market cap. It's a great deal but the current administration is quite wary of deals and claims this would be monopolistic. My view is that the case is weak, especially after the companies named a strong buyer for the entire overlapping product lines. The deal will probably get done by the middle of next year, which could catapult SPB shares regardless of what the rest of the market is doing. Antitrust I blurted out two edgy, actionable ideas – a favorite recent one and upcoming one. But now let me back up to discuss M&A heading into 2023 more generally. This category is a great solution for capital if you don’t know what the market is going to do next. But the solution has a few problems worth highlighting. First the aforementioned antitrust agencies: They're particularly hostile at the moment and will bring a lot of suits to block deals, especially customer-facing deals in tech or healthcare. I like cases such as SPB that are already in front of a judge. The FTC and DoJ can bring cases, but they have to make their case. I prefer to avoid getting hit with the stock price reaction to such suits and then load up when the government brings dumb ones likely to lose. Financing A second problem: The credit market for deal financing is quite weak. If buyers need to raise a lot of debt from banks for their deals, those deals are not likely to get done. While antitrust has been making life hard for strategic deals, the credit market has been making life particularly hard for private equity’s leveraged buyouts. In fact one of the best places in the market for short ideas in 2022 has been in speculated takeover candidates. Many of these made it into the press without making it to definitive merger agreements. So I like M&A but I'm wary of both antitrust risk and financing risk – what kind of deal does that leave me? Looking back at 2022, that left me Twitter, my biggest and best risk arbitrage position ever. Activision Looking forward, here are some of the opportunities. Microsoft (MSFT) is buying Activision (ATVI) in a deal that the FTC is trying to block on dubious antitrust grounds. They can delay it and even interfere enough to stop it, especially if they get an assist from foreign regulators such as the UK’s CMA. But the deal price is $95, as of this writing the shares cost about $77 and they aren’t worth all that much less than they cost even without the deal. So this was not worth it before the antitrust problems were fully priced in but is increasingly interesting since then. This may be one of the best definitive merger arbs at the moment, so is another I have my eye on. Amplify In terms of deal financing, eventually the credit market will stabilize. It doesn’t even need to strengthen as much as just settle down so participants know where to price debt. That’s why I’m focusing on situations for 2023 that need a few more months anyways. One in particular is Amplify Energy (AMPY). It costs about $7 per share and is worth at least twice that. The value is likely to be unlocked well before the end of next year. First, they have a damaged pipeline that needs fixing. Then, they have commodity hedges that can be rolled off. They will be able to use the repaired pipe for the cash flow necessary to completely deleverage their balance sheet. At which point, this wildly undervalued and undersized oil and gas company will be a layup of a sale candidate to a larger strategic buyer. This is safe, lucrative, uncorrelated, and likely to be a one-decision investment from here. If you can buy any under $10 per share, you will probably get a significant premium to that price in a sale. Ideally, the timing could work out so that it closes late enough in 2023 to get long-term tax treatment on what could be a monster gain. This is my biggest and favorite position at the moment (a best idea candidate, but it's volatile, so no decision until closer to Year End so I can see the starting price). Abiomed This one will actually be over (in terms of the window for taking advantage of it) by month end. It's a merger security that avoids any antitrust or financing risk. You could lose a little over a dollar (depending on the specific price you get) or make over $33. Johnson & Johnson (JNJ) is buying Abiomed (ABMD). It has already secured all regulatory approvals including the US, Germany, Austria, and Japan. Then by the end of this week they will tender for shares and send you $380 in cash per share, returning approximately your entire cost basis. That leaves you with, at worst, a tie. Then what? Then you get a non-tradable contingent value right worth up to $35. Sometimes these pay out, sometimes they don’t, and often they settle years later when holders sue the issuers over their treatment. You’re paying just over a dollar (I paid less than nothing) for a ticket that could settle or payout many times that. Details from the offer:
Seeking Alpha • Nov 10

Renren Non-GAAP EPS of $2.77, revenue of $21.3M

Renren press release (NYSE:RENN): 1H Non-GAAP EPS of $2.77. Revenue of $21.3M (+42.0% Y/Y).
Seeking Alpha • Apr 28

Renren: Our Best Long For 2022

How has RENN done so far? What is it worth? What happens next?
Seeking Alpha • Jan 19

Renren: An Update On Our Best Idea For 2022

Sifting the World presented our best idea to members last month. A lot has happened since then in the market and this stock. Here is why it is a huge opportunity today at under $25.
Seeking Alpha • Jan 10

Renren Is So Bad It's Good

StW’s best idea for 2022. A disastrous – but appealable – decision. An uncorrelated opportunity for the New Year.
Seeking Alpha • Oct 18

Renren In Search Of Identity As Its Stock Surges On Lawsuit Settlement

A 45% surge in shares of Renren, once pegged as the ‘Facebook of China,’ earlier this month was fueled by settlement of a shareholder lawsuit. Despite a $600 million market value after the jump, company is still in search of a long-term business model. In trying to stay alive and thrive during the years when its networking platform was in decline, Chairman Chen Yizhou steered Renren in a new direction by buying stakes in startups that had little to do with the social media.
Analyseartikel • Feb 15

What Type Of Shareholders Make Up Renren Inc.'s (NYSE:RENN) Share Registry?

If you want to know who really controls Renren Inc. ( NYSE:RENN ), then you'll have to look at the makeup of its share...

Aufschlüsselung der Einnahmen und Ausgaben

Wie Moatable Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

OTCPK:MTBL.Y Einnahmen, Ausgaben und Erträge (USD Millions)
DatumEinnahmenGewinnAllgemeine und VerwaltungskostenF&E-Ausgaben
30 Sep 2575-13523
30 Jun 257113421
31 Mar 256703420
31 Dec 2463-23219
30 Sep 2460-33418
30 Jun 2456-113217
31 Mar 2454-193218
31 Dec 2352-103318
30 Sep 2351-293318
30 Jun 2350-753418
31 Mar 2348-683417
31 Dec 2246-773516
30 Sep 2242-1093615
30 Jun 2239-613714
31 Mar 2235-833612
31 Dec 2132-1033411
30 Sep 21-4-46268
30 Jun 2125-49299
31 Mar 2122-31309
31 Dec 2018-143210
30 Jun 20176-1356920
31 Mar 20260-317122
31 Dec 1915182222
30 Sep 19389-726124
30 Jun 19450-447427
31 Mar 19475-1429127
31 Dec 1867-625922
30 Sep 18490-15411628
30 Jun 18437-17411027
31 Mar 18288-118118
31 Dec 1717597217
30 Sep 17124-1207920
30 Jun 1781-1496919
31 Mar 1774-1786819
31 Dec 1647-63538
30 Sep 1646-1447316
30 Jun 1648-2027520
31 Mar 1644-2287924
31 Dec 1541-2228227
30 Sep 1515-1347720
30 Jun 1563-839134

Qualität der Erträge: MTBL.Y ist derzeit unrentabel.

Wachsende Gewinnspanne: MTBL.Y ist derzeit unrentabel.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: MTBL.Y ist unrentabel, hat aber in den letzten 5 Jahren die Verluste mit einer Rate von 36.2% pro Jahr reduziert.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von MTBL.Y verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: MTBL.Y ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Software (11.7%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: MTBL.Y hat eine negative Eigenkapitalrendite (-6.9%), da es derzeit unrentabel ist.

Kapitalrendite

Rendite auf das eingesetzte Kapital

Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/05/20 07:41
Aktienkurs zum Tagesende2026/05/20 00:00
Gewinne2025/09/30
Jährliche Einnahmen2024/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Moatable, Inc. wird von 9 Analysten beobachtet. 0 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Alicia YapBarclays
Eddie LeungBofA Global Research
Muzhi LiCitigroup Inc